Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino
GeriPal
MARCH 9, 2023
FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Stacy: I honestly read Michael Pollan’s New Yorker article and was really inspired, and cold emailed the group at NYU, and they responded. Theora: Bryan shared that article with me. Eric: Yeah.
Let's personalize your content